Frank Rimerman Advisors LLC Grows Holdings in Humana Inc. (NYSE:HUM)

Frank Rimerman Advisors LLC boosted its holdings in shares of Humana Inc. (NYSE:HUM) by 28,250.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,134 shares of the insurance provider’s stock after purchasing an additional 1,130 shares during the period. Frank Rimerman Advisors LLC’s holdings in Humana were worth $424,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. grew its holdings in shares of Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares during the last quarter. Hantz Financial Services Inc. acquired a new position in shares of Humana in the second quarter valued at approximately $35,000. Family Firm Inc. purchased a new position in Humana during the 2nd quarter worth $37,000. Hollencrest Capital Management acquired a new stake in Humana in the second quarter valued at about $40,000. Finally, Riverview Trust Co acquired a new stake in shares of Humana in the 2nd quarter valued at approximately $44,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Down 0.2 %

Shares of NYSE:HUM opened at $312.29 on Wednesday. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The stock has a 50-day simple moving average of $354.61 and a 200-day simple moving average of $345.12. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The stock has a market capitalization of $37.63 billion, a P/E ratio of 19.45, a PEG ratio of 2.56 and a beta of 0.50.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same period in the prior year, the company earned $8.94 EPS. The firm’s revenue was up 10.4% on a year-over-year basis. Equities analysts forecast that Humana Inc. will post 16 earnings per share for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.13%. Humana’s payout ratio is currently 22.04%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. TD Cowen upped their price target on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Morgan Stanley started coverage on shares of Humana in a report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 target price for the company. Truist Financial boosted their price target on Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research note on Monday, July 15th. Royal Bank of Canada raised their price objective on Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, September 5th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 target price on shares of Humana in a research report on Friday, September 20th. Thirteen investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.